Similar articles

• KEYNOTE-024: Unlocking a pathway to lung cancer cure?

  Rusch VW, Chaft J, Hellmann M. Rusch VW, et al. J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23. J Thorac Cardiovasc Surg. 2018. PMID: 29395215 No abstract available.
• Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.

  Sibille A, Henket M, Corhay JL, Louis R, Duysinx B. Sibille A, et al. Acta Oncol. 2020 Mar;59(3):257-259. doi: 10.1080/0284186X.2019.1695063. Epub 2019 Nov 22. Acta Oncol. 2020. PMID: 31755328 No abstract available.
• [Immuno-checkpoint inhibitor resistance and strategy in lung cancer].

  Jiang WR, Fang LP, Chang N, Zhang J. Jiang WR, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):603-606. doi: 10.3760/cma.j.cn112147-20200312-00319. Zhonghua Jie He He Hu Xi Za Zhi. 2020. PMID: 32629564 Review. Chinese.
• Baseline corticosteroids reduce activity of PD-L1 blockade.

  Gourd E. Gourd E. Lancet Oncol. 2018 Oct;19(10):e515. doi: 10.1016/S1470-2045(18)30666-1. Epub 2018 Aug 31. Lancet Oncol. 2018. PMID: 30177497 No abstract available.
• Immunotherapeutic approaches for small-cell lung cancer.

  Iams WT, Porter J, Horn L. Iams WT, et al. Nat Rev Clin Oncol. 2020 May;17(5):300-312. doi: 10.1038/s41571-019-0316-z. Epub 2020 Feb 13. Nat Rev Clin Oncol. 2020. PMID: 32055013 Free PMC article. Review.